Randomized, controlled, phase 1/2 study of the safety and immunogenicity of AMA-C1/alhydrogel vaccine for Plasmodium falciparum malaria in children in Doneguebougou and Bancoumana, Mali.

Trial Profile

Randomized, controlled, phase 1/2 study of the safety and immunogenicity of AMA-C1/alhydrogel vaccine for Plasmodium falciparum malaria in children in Doneguebougou and Bancoumana, Mali.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Malaria vaccine (Primary) ; Aluminium hydroxide; Hib vaccine conjugate
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 18 May 2009 Results published in Vaccine.
    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
    • 11 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top